Characteristics of patients initiating PCSK9i mAb following myocardial infarction and comparability of treatment groups in the Netherlands

Back

ESC Professional Premium Access

Characteristics of patients initiating PCSK9i mAb following myocardial infarction and comparability of treatment groups in the Netherlands

Session: PCSK9 inhibitors and inclisiran

Topic: Lipid-Lowering Agents

Speaker: Doctor Q. Chan (Greater London, GB)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Queenie Chan

Amgen Ltd, Greater London (United Kingdom of Great Britain & Northern Ireland)

0 follower

8 more presentations in this session

Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT)

Speaker: Doctor C. Basile (Naples, IT)

Longer-term impact of PCSK9 inhibitors on major adverse cardiovascular events and all-cause mortality: a systematic review and meta-analysis of randomised controlled trials

Speaker: Ms J. Grover (Sydney, AU)

The effect of proprotein convertase subtilisin/kexin type 9 inhibition on the plasma proteome: a SPIRE sub-study

Speaker: Mr J. Kraaijenhof (Amsterdam, NL)

Efficacy and safety of alirocumab in children and adolescents with heterozygous familial hypercholesterolaemia inadequately controlled with statins

Speaker: Associate Professor R. Santos (Sao Paulo, BR)

Identification of potent small-molecule PCSK9 inhibitors based on quantitative structure-activity relationship, pharmacophore modeling, and molecular docking procedure.

Speaker: Professor M. Banach (Lodz, PL)

Access the full session

PCSK9 inhibitors and inclisiran

Speakers: Doctor Q. Chan, Doctor C. Basile, Ms J. Grover, Mr J. Kraaijenhof, Associate Professor R. Santos...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources